文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血管紧张素II用于休克:多中心上市后使用研究

Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use.
PubMed 文献 · Chest · 2020-08-31
一句话结论在血管加压药难治性休克中,67%的患者对血管紧张素II出现血流动力学反应,反应者30天死亡风险较低(HR 0.50)。

该多中心回顾性研究纳入5家美国三级医疗中心的270例血管加压药难治性休克患者,评估血管紧张素II上市后使用的安全性和有效性。主要终点为启动后3小时平均动脉压≥65 mmHg且总血管加压药剂量稳定或降低,67%(181例)达到血流动力学反应。反应者3小时平均动脉压升高(+10.3 mmHg vs +1.6 mmHg)且血管加压药剂量降低(-0.20 μg/kg/min vs +0.04 μg/kg/min),与非反应者相比差异有统计学意义。较低乳酸浓度和接受血管加压素与 favorable 反应相关;严重度调整多变量分析中,反应者30天死亡风险降低(HR 0.50)。

要点

  • 血管加压药难治性休克患者中,67%(181/270)在血管紧张素II启动后3小时达到血流动力学反应(MAP≥65 mmHg且血管加压药剂量稳定或降低)。
  • 反应者3小时MAP升高+10.3 mmHg,非反应者升高+1.6 mmHg(P<.001)。
  • 反应者3小时血管加压药剂量变化-0.20 μg/kg/min,非反应者+0.04 μg/kg/min(P<.001)。
  • 较低乳酸浓度(OR 1.11;95%CI 1.05-1.17)和接受血管加压素(OR 6.05;95%CI 1.98-18.6)与 favorable 血流动力学反应相关。
  • 严重度调整多变量分析中,血流动力学反应与30天死亡风险降低相关(HR 0.50;95%CI 0.35-0.71;P<.001)。

适用人群与场景

  • 血管加压药难治性休克患者,来自美国5家三级医疗中心。
  • 纳入接受血管紧张素II上市后使用的患者。

诊断标准与关键阈值

  • 血流动力学反应定义为启动血管紧张素II后3小时平均动脉压≥65 mmHg且总血管加压药剂量稳定或降低。

研究设计与关键结果

  • 多中心回顾性研究,纳入270例患者,181例(67%)出现血流动力学反应。
  • 反应者3小时MAP升高+10.3 mmHg vs 非反应者+1.6 mmHg(P<.001)。
  • 反应者3小时血管加压药剂量变化-0.20 μg/kg/min vs 非反应者+0.04 μg/kg/min(P<.001)。
  • 较低乳酸浓度(OR 1.11;95%CI 1.05-1.17;P<.001)和接受血管加压素(OR 6.05;95%CI 1.98-18.6;P=.002)与 favorable 血流动力学反应相关。
  • 严重度调整多变量分析中,血流动力学反应与30天死亡风险降低相关(HR 0.50;95%CI 0.35-0.71;P<.001)。
  • 心律失常发生于28例患者(10%),静脉血栓栓塞4例。

证据类型、等级与局限

  • 证据类型:多中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在血管加压药难治性休克患者中,血管紧张素II上市后使用后67%出现血流动力学反应,反应者30天死亡风险较低(HR 0.50)。
  • 较低乳酸浓度和接受血管加压素的患者更可能对血管紧张素II出现血流动力学反应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Vasodilatory shock refractory to catecholamine vasopressors and arginine vasopressin is highly morbid and responsible for significant mortality. Synthetic angiotensin II is a potent vasoconstrictor that may be suitable for use in these patients.

RESEARCH QUESTION: What is the safety and effectiveness of angiotensin II and what variables are associated with a favorable hemodynamic response?

STUDY DESIGN AND METHODS: We performed a multicenter, retrospective study at five tertiary medical centers in the United States. The primary end point of hemodynamic responsiveness to angiotensin II was defined as attainment of mean arterial pressure (MAP) of ≥ 65 mm Hg with a stable or reduced total vasopressor dosage 3 h after drug initiation.

RESULTS: Of 270 included patients, 181 (67%) demonstrated hemodynamic responsiveness to angiotensin II. Responders showed a greater increase in MAP (+10.3 mm Hg vs +1.6 mm Hg, P < .001) and reduction in vasopressor dosage (-0.20 μg/kg/min vs +0.04 μg/kg/min; P < .001) compared with nonresponders at 3 h. Variables associated with favorable hemodynamic response included lower lactate concentration (OR 1.11; 95% CI, 1.05-1.17, P < .001) and receipt of vasopressin (OR, 6.05; 95% CI, 1.98-18.6; P = .002). In severity-adjusted multivariate analysis, hemodynamic responsiveness to angiotensin II was associated with reduced likelihood of 30-day mortality (hazard ratio, 0.50; 95% CI, 0.35-0.71; P < .001). Arrhythmias occurred in 28 patients (10%) and VTE was identified in 4 patients.

INTERPRETATION: In postmarketing use for vasopressor-refractory shock, 67% of angiotensin II recipients demonstrated a favorable hemodynamic response. Patients with lower lactate concentrations and those receiving vasopressin were more likely to respond to angiotensin II. Patients who responded to angiotensin II experienced reduced mortality.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Wieruszewski PM, Wittwer ED, Kashani KB, et al. Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use. Chest. 2020. PMID: 32882250. doi:10.1016/j.chest.2020.08.2074

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。